Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
... and set up Czech center
July 24, 2006
| A version of this story appeared in
Volume 84, Issue 30
Gilead plans to provide $1.1 million annually for five years to the Institute of Organic Chemistry & Biochemistry at the Academy of Sciences of the Czech Republic (IOCB) to help establish a research facility. Gilead has licensing agreements with IOCB and the Rega Institute for Medical Research at Belgium's Katholic University dating back to 1991 for a range of nucleotide analog compounds and structures. Several of them have been developed by Gilead, resulting in the HIV treatment Viread and other drugs.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter